A pan-cancer analysis of the oncogenic and immunological roles of transglutaminase 1 (TGM1) in human cancer
Journal of Cancer Research and Clinical Oncology · 12.03.2024 · 150 (3)
DOI: 10.1007/s00432-024-05640-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cancer Research and Clinical Oncology, online erschienen am 12.03.2024. Verfasst von Ruicheng Wu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Institute of Urology, West China School of Medicine, West China Hospital, Sichuan University, Chengdu, 610041, China. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
There is currently a limited number of studies on transglutaminase type 1 (TGM1) in tumors. The objective of this study is to perform a comprehensive analysis across various types of cancer to determine the prognostic significance of TGM1 in tumors and investigate its role in the immune environment.
Method
Pan-cancer and mutational data were retrieved from the TCGA database and analyzed using R (version 3.6.4) and its associated software package. The expression difference and prognosis of TGM1 were examined, along with its correlation with tumor heterogeneity, stemness, mutation landscape, and RNA modification. Additionally, the relationship between TGM1 expression and tumor immunity was investigated using the TIMER method.
Results
TGM1 is expressed differently in various tumors and normal samples and is associated with the overall survival and progression-free time of KIRC, ACC, SKCM, LIHC, and STES. In LICH, we found a negative correlation between TGM1 expression and 6 indicators of tumor stemness. The mutation frequencies of BLCA, LIHC, and KIRC were 1.7%, 0.3%, and 0.3% respectively. In BLCA and BRCA, there was a significant correlation between TGM1 expression and the infiltration of CD4 + T cells, CD8 + T cells, neutrophils, and dendritic cells.
Conclusion
TGM1 has the potential to serve as both a prognostic marker and a drug target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Institute of Urology, West China School of Medicine, West China Hospital, Sichuan University, Chengdu, 610041, China.
- Research Core Facilities, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, People's Republic of China.
- Department of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei, 230601, China.
- Department of Rehabilitation, West Kyushu University, Fukuoka, Japan.
- Department of Urology, Kyung Hee University, Seoul, South Korea.
- Department of Rehabilitation, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, People's Republic of China.
Zitieren
APA
Wu, R., Li, D., Zhang, S., Wang, J., Chen, K., Tuo, Z., Miyamoto, A., Yoo, K. H., Wei, W., Zhang, C., Feng, D., & Han, P. (2024). A pan-cancer analysis of the oncogenic and immunological roles of transglutaminase 1 (TGM1) in human cancer. Journal of Cancer Research and Clinical Oncology, 150(3). https://doi.org/10.1007/s00432-024-05640-6
Vancouver
Wu R, Li D, Zhang S, Wang J, Chen K, Tuo Z, et al. A pan-cancer analysis of the oncogenic and immunological roles of transglutaminase 1 (TGM1) in human cancer. Journal of Cancer Research and Clinical Oncology. 2024;150(3). doi:10.1007/s00432-024-05640-6
BibTeX
@article{Wu2024,
author = {Wu, Ruicheng and Li, Dengxiong and Zhang, Shuxia and Wang, Jie and Chen, Kai and Tuo, Zhouting and Miyamoto, Akira and Yoo, Koo Han and Wei, Wuran and Zhang, Chi and Feng, Dechao and Han, Ping},
title = {A pan-cancer analysis of the oncogenic and immunological roles of transglutaminase 1 (TGM1) in human cancer},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2024},
volume = {150},
number = {3},
doi = {10.1007/s00432-024-05640-6}
}
EUVIMED